Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing Labetalol hydrochloride may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
for
Labetalol Synchrony contains the active substance Labetalol. This medicine belongs to a group of medicines called alpha and beta blockers. These medicines work by causing the heart to beat more slowly and with less force. It also widens the arteries in the body. The result is a rapid lowering of a person's blood pressure. Labetalol is given in hospital and can be used in the treatment of severe hypertension (high blood pressure), including severe hypertension during pregnancy (gestational hypertension), when the blood pressure needs to be lowered rapidly. This medicine may also be used to control the blood pressure during anaesthesia and to lower high blood pressure after a heart attack. It is very important that the doctor treats your high blood pressure, because left untreated it can cause damage to your blood vessels in the long-term. This could lead to heart attacks, kidney failure, stroke or blindness.
2.
Labetalol Synchrony
You should NOT be given this medicine if: you are allergic to labetalol or any of the other ingredients of this medicine (listed in section 6) your heart cannot maintain adequate circulation of blood (cardiogenic shock) you have heart failure that is out of control or not responding to treatment with digitalis you have a heart defect that leads to a decreased function of the heart (heart block) your heart has difficulty pumping the proper amount of blood to the body's tissues you have a problem that is common in the elderly, related to poor control of the working of your heart (sick sinus syndrome) you have low blood pressure (hypotension) you have a weak heart or a very slow heartbeat (less than 45 or 50 beats per minute) you suffer from angina (chest pains) when at rest you suffer from wheezing, obstructive airways disease or asthma – taking labetalol can make your breathing worse you have a tumour near your kidneys (phaeochromocytoma) you have increased acid levels in the blood (metabolic acidosis) you have very bad circulation, especially in your hands and feet 1
If any of the above applies to you, talk to your doctor. Warnings and precautions Talk to your doctor or nurse before you are treated with Labetalol Synchrony if: you are about to receive an anaesthetic: as labetalol may mask the effects of a sudden loss of blood you suffer or have suffered from any serious allergic reactions in the past you have ever suffered from a skin condition called psoriasis you have kidney or liver problems you are receiving a procedure called MIBG scintigraphy (often used to detect certain tumours) you are elderly (65 years and over) you are scheduled for cataract surgery as labetalol may affect your pupils during this procedure. Please tell your eye surgeon before your surgery about your treatment with this medicine. You do not need to stop treatment with this medicine unless your surgeon advises otherwise your heart rate slows to less than 50 -55 beats per minute while at rest (bradycardia) you have a reduced blood supply to the heart muscle (ischaemic heart disease) you have poor circulation e.g. fingers and toes go numb and pale (Raynaud's syndrome) or you sometimes limp (intermittent claudication) you have an irregular heart beat (first degree atrioventricular block) If treatment with this medicine leads to a slow heartbeat (bradycardia) your doctor may lower your dosage. If you suffer from skin rash, dry eyes, or an allergic reaction during your treatment with this medicine, please contact your doctor for the dosage to be lowered or the treatment to be discontinued. Other medicines and Labetalol Synchrony Tell your doctor or nurse if you are taking, have recently taken or might take any other medicines. In particular tell your doctor if you are taking any of the following: Medicines used to treat your heart or blood pressure (such as digitalis, clonidine, hydralazine, disopyramide, quinidine, amiodarone, calcium antagonists such as verapamil, alpha blockers such as doxazosin, diltiazem, nifedipine, ACE inhibitors, angiotensin-II antagonists, xamoterol and diuretics (water tablets). Medicines to treat depression (such as monoamine oxidase inhibitors or tricyclic antidepressants). Anxiolytic and hypnotic medicines for anxiety and sedation NSAIDs, corticosteroids or other medicines to treat pain or inflammatory conditions Cimetidine used to treat stomach ulcers. Medicines for stimulating the heart e.g. adrenaline Anaesthetic drugs (such as cyclopropane, trichloroethylene, alcohol, barbiturates) Insulin or oral anti-diabetic drugs Ergot derivatives used to treat Parkinson's disease Phenothiazines such as chlorpromazine Antimalarial medicines such as halofantrine, mefloquine or quinine Tropisetron used to treat nausea. Alprostadil and moxisylyte to treat impotence Aldesleukin for the treatment of secondary cancer of the kidney Hormones such as oestrogen and progesterone used as contraceptives or for hormone replacement therapy Any other medicine, including medicines obtained without a prescription. Taking labetalol at the same time as the drugs mentioned for treating your heart or blood pressure, can lead to a severe drop in blood pressure, reduced heart rate, heart failure or heart block. It is important to tell your doctor if you are taking these or any of the other drugs listed above. 2
Tests This medicine may have a disruptive effect on certain medical or laboratory tests. This may lead to incorrect test results. Tell your doctor and the laboratory staff that you have been given this medicine if you need to have a blood or urine test. Pregnancy, breast-feeding and fertility. Labetalol should only be used during the first three months of pregnancy if it is absolutely necessary. If you are pregnant or think you may be pregnant or are planning to have ask your doctor for advice before being treated with this medicine. Nipple pain and Raynaud's phenomenon of the nipple have been reported (see section 4). Labetalol is not recommended whilst breast-feeding. Driving and using machines You may feel dizzy or tired when taking labetalol. If this happens to you, do not drive or operate machinery. Important information about some of the other ingredients in Labetalol Synchrony This medicinal product contains less than 1mmol (23mg) of sodium (salt) per vial, i.e. essentially sodium (salt) free. 3.
Labetalol Synchrony
This medicine always needs to be used as prescribed by your doctor. It is intended for intravenous treatment in hospitalized patients and needs to be given by a healthcare professional. Remember: This drug should only be given if you are lying down. You should avoid sitting upright for three hours after being given this medicine, as you may feel very dizzy and lightheaded (due to low blood pressure). This medicine may be given as a bolus injection (which means that it will be given directly into a vein), or by intravenous infusion (which means that it will be given as a slow drip into a vein). IMPORTANT: Your doctor will decide how this medicine will be given to you and the correct dose for you. While you are having Labetalol Synchrony your doctor may check your heart rate, blood pressure and breathing, to check your medicine is working properly. Adults: Injection into a vein (to reduce blood pressure very quickly)
–
15mg of Labetalol Synchrony will be given over one hour. The dose may then be gradually increased up to a maximum of 120mg per hour if needed.
3. To lower high blood pressure for other reasons
Like all medicines, this medicine can cause side effects, although not everybody gets them. Serious side effects Remember: You should avoid sitting upright for three hours after being given Labetalol Synchrony as you may feel very dizzy and lightheaded. Tell your doctor or nurse immediately if you have an allergic reaction. This includes any of the following symptoms: difficulty in breathing swelling of your eyelids, face or lips rash or itching Other side effects Common (may affect up to 1 in 10 people) 4
–
Congestive heart failure Dizziness due to low blood pressure when sitting upright or standing up too quickly (postural hypotension). This can happen within the first three hours after this medicine has been given, and is short-lasting in nature. This will occur in the first weeks of treatment. Nasal congestion, this is usually short-lived and will occur in the first weeks of treatment Increased liver function. This will usually be short-lived after treatment has stopped. Erectile dysfunction (impotency).
Rare (may affect up to 1 in 1,000 people) Slow heart beat which can be measured by a low pulse (bradycardia). Constriction of the muscles in the walls of the bronchioles causing breathlessness (bronchospasm). Very rare (may affect up to 1 in 10,000 people) Blocking of the electrical signals controlling the heart rhythm (heart block) Worsening of blood circulation leading to nipple pain, cold or blue extremities with numbness or tingling in your fingers and toes Inflammation of the liver (hepatitis), usually short-lived when the treatment is discontinued. Hepatocellular jaundice (skin and whites of the eyes become yellow), cholestatic jaundice (symptoms include tiredness and nausea followed by itchiness, dark urine, and jaundice, and also skin rash and fever) and liver necrosis (damaged liver tissue). These symptoms will disappear after the treatment with this medicine has stopped. Not known (cannot be estimated from the available data) –
Nipple pain Intermittent decrease in blood flow to your nipples, which may cause your nipples to go numb, pale, and painful (Raynaud's phenomenon)
Most of the side effects related to Labetalol Synchrony will wear off after the first few weeks. These include:
–
muscle disease (toxic myopathy) causing weakness and wasting of the muscles in the arms and legs flat topped bumps on your skin that join up into scaly patches (lichenoid rash) blurred vision or dry eyes cramps cough or breathing problems that may indicate inflammation of the lungs (interstitial lung disease)
Rare side effects on your baby If you are being treated for high blood pressure during pregnancy, your baby may suffer the following effects for a few days after birth:
Labetalol Synchrony
Keep the ampoules in the original packaging (to protect from light). Keep this medicine out of the sight and reach of children. Do not use Labetalol Synchrony after the expiry date which is stated on the carton and the ampoule label. The expiry date refers to the last day of that month. Any unused dilution should be disposed of after 24 hours. Discard any unused material. Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist what to do with any leftover medicine. These measurements will protect the environment. 6.
What Labetalol contains The active ingredient is labetalol hydrochloride. The other ingredients are dilute hydrochloric acid (E507), sodium hydroxide (E524) for pH adjustment, and water for injections. What Labetalol looks like and contents of the pack Labetalol is a clear colourless solution. Labetalol comes in 10ml amber glass ampoules with a white break ring, with ten ampoules in each pack. Marketing Authorisation Holder Synchrony Pharma Ltd, 3 Bunhill Row, London EC1Y 8YZ, United Kingdom Manufacturer Kleva SA, 189 Parnithos Ave, 136 75 Acharnes, Greece 6
This leaflet was last revised in April 2024 <————————————————————————————————————————> The following information is intended for healthcare professionals only: Administration Labetalol Synchrony is meant for intravenous use in hospitalized patients and should always be given by healthcare professionals. Patients should always receive the drug whilst in the supine or left lateral position. Raising the patient into the upright position within 3 hours of intravenous labetalol administration should be avoided since severe postural hypotension may occur. It is desirable to check the blood pressure and heart rate after the injection and during the infusion. The heart rate will decrease slightly. Severe bradycardia is not usual, but can be controlled by an intravenous injection of 1 to 2mg of atropine. The breathing should be carefully checked in patients with known airway disease. Labetalol Synchrony can be given as a bolus injection or intravenously. Labetalol Synchrony injection is administered to patients who suffer from uncontrolled hypotension and who have been given other hypotensive substances, including beta- blockers, without suffering from side effects. Oral maintenance When the blood pressure has been lowered sufficiently through either the bolus injection or intravenously, the treatment should be maintained by labetalol tablets with a starting dose of 100mg, twice a day. Indication
Dosage
Severe hypertension
Bolus injection: If it is essential to reduce blood pressure quickly, as for example in hypertensive encephalopathy, a dose of 50mg of labetalol hydrochloride should be given by intravenous injection (over a period of at least one minute). If necessary, doses of 50mg may be repeated at five minute intervals until a satisfactory response occurs. The total dosage should not exceed 200mg. After bolus injection, the maximum effect usually occurs within five minutes and the effective duration of action is usually about 6 hours but may be as long as 18 hours.
7
Intravenous infusion An alternative method of administering labetalol is intravenous infusion of a solution made by diluting the contents of four 10ml ampoules (200mg) to 200ml with Sodium Chloride and Dextrose Injection or 5% Dextrose Intravenous Infusion or Potassium Chloride and Glucose solution or Ringer Lactate. The resultant infusion solution contains 1 mg/ml of labetalol hydrochloride. It should be administered using a paediatric giving set fitted with a 50 ml graduated burette to facilitate dosage. In hypertension due to other causes: The rate of infusion of labetalol hydrochloride should be about 2mg (2ml of infusion solution) per minute, until a satisfactory response is obtained; the infusion should then be stopped. The effective dose is usually in the range of 50200mg depending on the severity of the hypertension. For most patients it is unnecessary to administer more than 200mg but larger doses may be required, especially in patients with phaeochromocytoma. The rate of infusion may be adjusted according to the response, at the discretion of the physician. The blood pressure and pulse rate should be monitored throughout the infusion. It is desirable to monitor the heart rate after injection and during infusion. In most patients, there is a small decrease in the heart rate; severe bradycardia is unusual but may be controlled by injecting atropine 1-2 mg intravenously. Respiratory function should be observed particularly in patients with any known impairment. Once the blood pressure has been adequately reduced, maintenance therapy with labetalol tablets should be instituted with a starting dose of one 100 mg tablet twice daily (see labetalol tab-let SmPC for further details). Labetalol Synchrony has been administered to patients with uncontrolled hypertension already receiving other hypotensive agents, including beta-blocking drugs, without adverse effects. In the hypertension of pregnancy: In severe cases of hypertension of pregnancy a lower, increasing infusion rate needs to be administered. The infusion needs to be started at the rate of 20mg/ hour, and this dose may be doubled every 30 minutes until a satisfactory result has been obtained, or a dosage of 160mg/hour is reached. Occasionally, higher doses may be necessary. In hypertensive episodes following acute myocardial infarction: The infusion should be commenced at 15mg per hour and gradually increased to a maximum of 120mg per hour depending on the control of blood pressure.
8
Hypotensive Anaesthesia
Induction should be with standard agents (e.g. sodium thiopentone) and anaesthesia maintained with nitrous oxide and oxygen with or without halothane. The recommended starting dose of Labetalol injection is 10-20mg intravenously, depending on the age and condition of the patient. Patients for whom halothane is contraindicated usually require a higher initial dose of labetalol hydrochloride (25-30 mg). If satisfactory hypotension is not achieved after five minutes, increments of 5-10mg should be given until the desired level of blood pressure is attained. Halothane and labetalol act synergistically therefore the halothane concentration should not exceed 1-1.5% as profound falls in blood pressure may be precipitated. Following labetalol injection the blood pressure can be quickly and easily adjusted by altering the halothane concentration and/or adjusting table tilt. The mean duration of hypotension following 20 to 25mg of labetalol is 50 minutes. Hypotension induced by labetalol injection is readily reversed by atropine 0.6 mg and discontinuation of halothane. Tubocurarine and pancuronium may be used when assisted or controlled ventilation is required. Intermittent Positive Pressure Ventilation (IPPV) may further increase the hypotension resulting from labetalol injection and/or halothane.
Paediatric patients The safety and efficacy of labetalol administered to children between 0 to 18 years of age have not been established. No data is available. Compatibility Labetalol injection is compatible with the following solutions for infusion Dextrose 5% (w/v) Sodium Chloride 0.18% (w/v) and dextrose 4% (w/v) Potassium Chloride 0.2% (w/v) and glucose 5% (w/v) Ringer Lactate Incompatibilities Labetalol injection has been shown to be incompatible with sodium bicarbonate injection 4.2% w/v Overdose Signs and symptoms: Symptoms of overdosage are bradycardia, hypotension, bronchospasm and acute cardiac insufficiency. Oliguric renal failure has been reported after massive overdosage of labetalol orally. In one case, the use of dopamine to increase the blood pressure may have aggravated the renal failure. Labetalol does have membrane stabilising activity which may have clinical significance in overdosage. 9
Treatment: After an overdose or in case of hypersensitivity, the patient should be kept under close supervision and be treated in an intensive-care ward. Artificial respiration may be required. Bradycardia or extensive vagal reactions should be treated by administering atropine or methylatropine. Hypotension and shock should be treated with plasma/plasma substitutes and, if necessary, catecholamines. The beta-blocking effect can be counteracted by slow intravenous administration of isoprenaline hydrochloride, starting with a dose of approximately 5mcg/min, or dobutamine, starting with a dose of approximately 2.5mcg/min, until the required effect has been obtained. If this does not produce the desired effect, intravenous administration of 8-10 mg glucagon may be considered. If required the injection should be repeated within one hour, to be followed, if necessary, by an IV infusion of glucagon at 1-3 mg/hour. Administration of calcium ions, or the use of a cardiac pacemaker, may also be considered. Haemodialysis removes less than 1% labetalol hydrochloride from the circulation. Shelf Life Chemical and physical in-use stability diluted in dextrose 5% (w/v); sodium chloride 0.18% (w/v) and dextrose 4% (w/v); potassium chloride 0.3% (w/v) and dextrose 5% (w/v) and Ringer Lactate has been demonstrated for 24 hours at 25 oC. From a microbiological point of view, the product should be used immediately after dilution. If not used immediately in-use storage time and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2 to 8°C, unless dilution has taken place in controlled and validated aseptic conditions. Any unused dilution should be disposed after 24 hours.
10
Labetalol Synchrony 5mg/ml solution for injection comes as injection containing 5mg/ml. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.
The active substance in Labetalol Synchrony 5mg/ml solution for injection is labetalol hydrochloride.
Medicines with the same active substance, strength and form include: Labetalol Hydrochloride 5mg/ml Solution for Injection. They are interchangeable only if your prescriber or pharmacist says so.
This leaflet reproduces the patient information leaflet approved for Labetalol Synchrony 5mg/ml solution for injection, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
Labetalol Injection is indicated for the treatment of:
- Severe hypertension, including severe hypertension of pregnancy, when rapid control of blood pressure is essential.
- Anaesthesia when a hypotensive technique is indicated.
- Hypertensive episodes following acute myocardial infarction.
Adults:
Labetalol injection is intended for intravenous use in hospitalised patients. The plasma concentrations achieved after intravenous dose of labetalol in severe hypertension are substantially greater than those following oral administration of the drug and provide a greater degree of blockade of alpha-adrenoceptors necessary to control the more severe disease. Patients should, therefore, always receive the drug whilst in the supine or left lateral position. Raising the patient into the upright position, within three hours of intravenous labetalol administration, should be avoided since excessive postural hypotension may occur.
Indication
Dosage
Severe hypertension
Bolus injection:
If it is essential to reduce blood pressure quickly, as for example in hypertensive encephalopathy, a dose of 50mg of labetalol hydrochloride should be given by intravenous injection (over a period of at least one minute). If necessary, doses of 50mg may be repeated at five minute intervals until a satisfactory response occurs. The total dosage should not exceed 200mg.
After bolus injection, the maximum effect usually occurs within five minutes and the effective duration of action is usually about 6 hours but may be as long as 18 hours.
Intravenous infusion
(instructions for dilution - refer to section 6.6)
An alternative method of administering labetalol is intravenous infusion of a solution made by diluting the contents of four 10ml ampoules (200mg) to 200ml with Sodium Chloride and Dextrose Injection, 5% dextrose Intravenous Infusion, Potassium Chloride and Glucose solution or Ringer Lactate. The resultant infusion solution contains 1 mg/ml of labetalol hydrochloride. It should be administered using a paediatric giving set fitted with a 50 ml graduated burette to facilitate dosage.
In hypertension due to other causes: The rate of infusion of labetalol hydrochloride should be about 2mg (2ml of infusion solution) per minute, until a satisfactory response is obtained; the infusion should then be stopped. The effective dose is usually in the range of 50-200mg depending on the severity of the hypertension. For most patients it is unnecessary to administer more than 200mg but larger doses may be required, especially in patients with phaeochromocytoma. The rate of infusion may be adjusted according to the response, at the discretion of the physician. The blood pressure and pulse rate should be monitored throughout the infusion.
It is desirable to monitor the heart rate after injection and during infusion. In most patients, there is a small decrease in the heart rate; severe bradycardia is unusual but may be controlled by injecting atropine 1-2 mg intravenously.
Respiratory function should be observed particularly in patients with any known impairment.
Once the blood pressure has been adequately reduced, maintenance therapy with labetalol tablets should be instituted with a starting dose of one 100 mg tablet twice daily (see labetalol tablet SmPC for further details).
Labetalol Injection has been administered to patients with uncontrolled hypertension already receiving other hypotensive agents, including beta-blocking drugs, without adverse effects.
In the hypertension of pregnancy: In severe cases of hypertension of pregnancy a lower, increasing infusion rate needs to be administered. The infusion needs to be started at the rate of 20mg/ hour, and this dose may be doubled every 30 minutes until a satisfactory result has been obtained, or a dosage of 160mg/hour is reached. Occasionally, higher doses may be necessary.
In hypertensive episodes following acute myocardial infarction: The infusion should be commenced at 15mg per hour and gradually increased to a maximum of 120mg per hour depending on the control of blood pressure.
Hypotensive Anaesthesia
Induction should be with standard agents (e.g. sodium thiopentone) and anaesthesia maintained with nitrous oxide and oxygen with or without halothane. The recommended starting dose of Labetalol injection is 10-20mg intravenously, depending on the age and condition of the patient. Patients for whom halothane is contraindicated usually require a higher initial dose of labetalol hydrochloride (25-30 mg).
If satisfactory hypotension is not achieved after five minutes, increments of 5-10mg should be given until the desired level of blood pressure is attained.
Halothane and labetalol act synergistically therefore the halothane concentration should not exceed 1-1.5% as profound falls in blood pressure may be precipitated.
Following labetalol injection the blood pressure can be quickly and easily adjusted by altering the halothane concentration and/or adjusting table tilt.
The mean duration of hypotension following 20 to 25mg of labetalol is 50 minutes.
Hypotension induced by labetalol injection is readily reversed by atropine 0.6 mg and discontinuation of halothane.
Tubocurarine and pancuronium may be used when assisted or controlled ventilation is required. Intermittent Positive Pressure Ventilation (IPPV) may further increase the hypotension resulting from labetalol injection and/or halothane.
Paediatric population:
The safety and efficacy of Labetalol administered to children from 0 to 18 years of age have not been established. No data are available
• Hypersensitivity to the active substance, or any of the excipients listed in section 6.1
• History of wheezing or asthma.
• Second or third degree heart block.
• Cardiogenic shock.
• Hypotension.
• Bradycardia (<45-50bpm).
• Uncontrolled, incipient or digitalis refractory heart failure.
• Sick sinus syndrome (including sino-atrial block).
• Prinzmetal's angina.
• Untreated phaechromocytoma
• Metabolic acidosis
• Severe peripheral circulatory disturbances.
Where peripheral vasoconstriction suggests low cardiac output, the use of labetalol to control hypertensive episodes following acute myocardial infarction is contra-indicated.
Liver Disease
There have been rare reports of severe hepatocellular injury with labetalol therapy. The hepatic injury is usually reversible and has occurred after both short and long term treatment. There have been reports of fatal hepatic necrosis. Appropriate laboratory testing should be done at the first sign or symptom of liver dysfunction. If there is laboratory evidence of liver injury or the patient is jaundiced, labetalol therapy should be stopped and not re-started.
Extra caution needs to be taken when labetalol is used in patients with liver dysfunction, as these patients metabolize labetalol slower than patients without liver dysfunction.
Peripheral circulatory disorders
In patients with peripheral circulatory disorders (Raynaud's disease or syndrome, intermittent claudication), beta-blockers should be used with great caution as aggravation of these disorders may occur.
Symptomatic Bradycardia
Beta-blockers may induce bradycardia. If the pulse rate decreases to less than 50-55 beats per minute at rest and if the patient experiences symptoms related to bradycardia, the dosage of Labetalol should be reduced.
First degree atrioventricular block
Due to the negative effect of beta-adrenergic blocking agents on the atrioventricular conduction time, labetalol needs to be administered with caution to patients with first degree atrioventricular block. Patients with liver or kidney insufficiency may need a lower dosage, depending on the pharmacokinetic profile of the compound. The elderly should be treated with caution, starting with a lower dosage but tolerance is usually good in the elderly.
Hypersensitivity to beta-blockers
Risk of anaphylactic reaction: While taking beta-blockers, patients with a history of severe anaphylactic reaction to a variety of allergens may be more reactive to repeated challenge, either accidental, diagnostic or therapeutic. Such patients may be unresponsive to the usual doses of epinephrine used to treat allergic reactions.
Skin rashes and/or dry eyes
There have been reports of skin rashes and/or dry eyes associated with the use of beta-adrenoceptor blocking drugs. The reported incidence is small and in most cases the symptoms have cleared when the treatment was withdrawn. Gradual discontinuation of the drug should be considered if any such reaction is not otherwise explicable.
Intraoperative floppy iris syndrome
The occurrence of intraoperative floppy iris syndrome (IFIS, a variation of Horner's syndrome) has been observed during cataract surgeries in some patients who were being treated with tamsulosine, or have been treated with tamsulosine in the past. IFIS has also been reported when other alpha-1- blockers were being used, and the possibility of a class effect cannot be excluded. Since IFIS can lead to a higher chance of complications during cataract surgeries, the ophthalmologist needs to be informed if alpha-1- blockers are currently being used, or have been used in the past.
Heart failure or ischemic heart disease
Due to negative inotropic effects, special care should be taken with patients whose cardiac reserve is poor and heart failure should be controlled before starting labetalol therapy.
Patients, particularly those with ischemic heart disease, should not interrupt or discontinue abruptly labetalol therapy. The dosage should gradually be reduced, i.e. over 1-2 weeks, if necessary at the same time initiating replacement therapy, to prevent exacerbation of angina pectoris. In addition, hypertension and arrhythmias may develop.
Anaesthetics
It is not necessary to discontinue labetalol therapy in patients requiring anaesthesia, but the anaesthetist must be informed and the patient should be given intravenous atropine prior to induction. During anaesthesia labetalol may mask the compensatory physiological responses to sudden haemorrhage (tachycardia and vasoconstriction). Close attention must therefore be paid to blood loss, and the blood volume maintained.
Anaesthetic agents causing myocardial depression (e.g. cyclopropane, trichloroethylene) should be avoided. Labetalol may enhance the hypotensive effects of halothane.
Asthma and obstructive airways disease
Beta-blockers, even those with apparent cardioselectivity, should not be used in patients with asthma or a history of obstructive airways disease unless no alternative treatment is available. In such cases the risk of inducing bronchospasm should be appreciated and appropriate precautions taken. If bronchospasm should occur after the use of labetalol it can be treated with a beta2-agonist by inhalation, e.g. salbutamol (the dose of which may need to be greater than the usual in asthma) and, if necessary, intravenous atropine 1mg.
Psoriasis
Patients with a history of psoriasis should take beta-blockers only after careful consideration.
Sodium
This medicinal product contains less than 1mmol sodium (23mg) per dose, that is to say essentially 'sodium-free'.
Concomitant use not recommended:
• Calcium antagonists such as verapamil and to a lesser extent diltiazem have a negative influence on contractility and atrio-ventricular conduction. Digitalis glycosides used in association with beta-blockers may increase atrioventricular conduction time. Labetalol can heighten the effect of digoxin on the reduction of ventricular flow.
• Clonidine: Beta-blockers increase the risk of rebound hypertension. When clonidine is used in conjunction with non-selective beta-blockers, such as propranolol, treatment with clonidine should be continued for some time after treatment with the beta-blocker has been discontinued.
• Monoamineoxidase inhibitors (except MOA-B inhibitors).
Use with caution:
• Class I antiarrhytmic agents (e.g. disopyramide, quinidine) and amiodarone (antiarrhytmic Class II) may have potentiating effects on atrial conduction and induce negative inotropic effect.
• Insulin and oral antidiabetic drugs may intensify the blood sugar lowering effect, especially of non-selective beta-blockers. Beta-blockade may prevent the appearance of signs of hypoglycemia (tachycardia). Anaesthetic drugs may cause attenuation of reflex tachycardia and increase the risk of hypotension. Continuation of beta-blockade reduces the risk of arrhythmia during induction and intubationa, The anaesthesiologist should be informed when the patient is receiving a beta-blocking agent. Anaesthetic agents causing myocardial depression, such as cyclopropane and trichlorethylene, are best avoided.Cimetidine, hydralazine and alcohol may increase the bioavailability of labetalol.
• Several different drugs or drug classes may enhance the hypotensive effects of labetalol: ACE inhibitors; angiotensin-II antagonists; aldesleukin, alprostadil; anxiolytics; hypnotics; moxisylyte; diuretics; alpha-blockers.
• Several different drugs or drug classes may antagonise the hypotensive effects of labetalol: NSAIDs, corticosteroids; oestrogens; progesterones
Take into account:
• Calcium antagonists: dihydropyridine derivates such as nifedipine, The risk of hypotension may be increased. In patients with latent cardiac insufficiency, treatment with beta-blockers may lead to cardiac failure. Prostaglandin synthetase inhibiting drugs may decrease the hypotensive effect of beta-blockers.
• Sympathicomimetic agents may counteract the effect of beta-adrenergic blocking agents.
• Concomitant use of tricyclic antidepressants, barbiturates, phenothiazines or other antihypertensive agents may increase the blood pressure lowering effect of labetalol. Concomitant use of tricyclic antidepressant may increase the incidence of tremor.
• Labetalol has been shown to reduce the uptake of radioisotopes of metaiodobenzylguanidine (MIBG), and may increase the likelihood of a false negative study. Care should therefore be taken in interpreting results from MIBG scintigraphy. Consideration should be given to withdrawing labetalol for several days at least before MIBG scintigraphy, and substituting other beta or alpha-blocking drugs.
• Antimalarials such as mefloquine or quinine may increase the risk of bradycardia.
• Ergot derivatives may increase the risk of peripheral vasoconstriction.
• Tropisetron may increase the risk of ventricular arrhythmia.
• Labetalol interferes with laboratory tests for catecholamines.
Pregnancy:
Although no teratogenic effects have been demonstrated in animals, labetalol should only be used during the first trimester of pregnancy if the potential benefit outweighs the potential risk. Labetalol crosses the placenta barrier and the possibility of the consequences of alpha- and beta- adreneceptor blockade in the foetus and neonate should be borne in mind. Perinatal and neonatal distress (bradycardia, hypotension, respiratory depression, hypoglycemia,hypothermia) has been rarely reported. Sometimes these symptoms have developed a day or two after birth. Response to supportive measures (e.g. intravenous fluids and glucose) is usually prompt but with severe pre-eclampsia, particularly after prolonged intravenous labetalol, recovery may be slower. This may be related to diminished liver metabolism in premature babies. Beta-blockers reduce placental perfusion, which may result in intrauterine foetal death, immature and premature deliveries. There is an increased risk of cardiac and pulmonary complications in the neonate in the post-natal period.
Intra-uterine and neonatal deaths have been reported with labetalol but other drugs (e.g. vasodilators, respiratory depressants) and the effects of preeclampsia, intra-uterine growth retardation and prematurity were implicated. Such clinical experience warns against unduly prolonging high dose labetalol and delaying delivery and against co-administration of hydralazine.
Breast-feeding:
Labetalol is excreted in breast milk. Breast-feeding is therefore not recommended. Nipple pain and Raynaud's phenomenon of the nipple have been reported (see section 4.8). Monitoring is needed if Labetalol is used in lactating mothers.
Fertility:
There is no information available on the effect labetalol has on the fertility.
There are no studies on the effect of this medicine on the ability to drive. When driving vehicles or operating machines it should be taken into account that occasionally dizziness or fatigue may occur.
Summary of safety profile
Labetalol injection is usually well tolerated. Excessive postural hypotension may occur if patients are allowed to assume an upright position within three hours of receiving labetalol injection.
Tabulated list of undesirable effects
The frequency of adverse reactions is defined as follows:
Very common ≥ 1/10
Common ≥ 1/100 <1/10
Sometimes ≥ 1/1000 <1/100
Rarely ≥ 1/10,000 < 1/1000
Very rarely < 1/10,000
Undesirable effects marked with a hash sign (#), Most side-effects are transient and occur during the first few weeks of treatment with labetalol.
They include:
System Organ Class
Undesired effect
Cardiac disorders
Common
Congestive heart failure
Rarely
Bradycardia
Very rarely
Heart block
Vascular disorder
Common
Postural hypotension
Very rarely
Worsening of the symptoms of Raynaud's syndrome
Respiratory, thoracic, and mediastinal disorders
Common
Nasal congestion
Rarely
Bronchospasm
Hepato-biliary disorders
Common
Raised liver function tests
Very rarely
Hepatitis, hepatocellular jaundice cholestatic jaundice, hepatic necrosis
Reproductive system and breast disorders
Common
Erectile dysfunction
Frequency not known
Nipple pain, Raynaud's phenomenon of the nipple
Description of some undesired effects:
Blood and the lymphatic system disorders
Rare reports of positive antinuclear antibodies unassociated with disease, hyperkalaemia, particularly in patients who may have impaired renal excretion of potassium, thrombocytopenia.
Psychiatric disorders
Depressed mood and lethargy, hallucinations, psychoses, confusion, sleep disturbances, nightmares.
Nervous system disorders
Headache, tiredness, dizziness, tremor has been reported in the treatment of hypertension of pregnancy.
Eye disorders
Impaired vision, dry eyes.
Respiratory, thoracic and mediastinal disorders
Bronchospasm (in patients with asthma or a history of asthma), nasal congestion, interstitial lung disease.
Gastrointestinal disorders
Epigastric pain, nausea, vomiting, diarrhoea.
Skin and subcutaneous tissue disorders
Sweating, tingling sensation in the scalp, usually transient, may occur in a few patients early in treatment, reversible lichenoid rash, systemic lupus erythematosus, exacerbation of psoriasis.
Musculoskeletal, connective tissue and bone disorders:
Cramps, toxic myopathy.
Renal and urinary disorders
Acute retention of urine, difficulty in micturition.
General disorders and administration site conditions
Drug fever, masking of the symptoms of thyrotoxicosis or hypoglycaemia, reversible alopecia.
Immune system disorder:
Reports of hypersensitivity include rash, pruritus, angioedema and dyspnea.
Vascular disorders:
Ankle oedema, increase of an existing intermittent claudication, cold or cyanotic extremities, Raynaud's phenomenon, paraesthesia of the extremities.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions through the Yellow Card Scheme. Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
Symptoms of overdosage:
Symptoms of overdosage are bradycardia, hypotension, bronchospasm and acute cardiac insufficiency Oliguric renal failure has been reported after massive overdosage on labetalol orally. In one case, the use of dopamine to increase the blood pressure may have aggravated the renal failure.
Labetalol does have membrane stabilising activity which may have clinical significance in overdosage.
Treatment:
After an overdose or in case of hypersensitivity, the patient should be kept under close supervision and be treated in an intensive-care ward. Artificial respiration may be required. Bradycardia or extensive vagal reactions should be treated by administering atropine or methylatropine. Hypotension and shock should be treated with plasma/plasma substitutes and, if necessary, catecholamines. The beta-blocking effect can be counteracted by slow intravenous administration of isoprenaline hydrochloride, starting with a dose of approximately 5mcg/min, or dobutamine, starting with a dose of approximately 2.5mcg/min, until the required effect has been obtained. If this does not produce the desired effect, intravenous administration of 8-10 mg glucagon may be considered. If required the injection should be repeated within one hour, to be followed, if necessary, by an iv infusion of glucagon at 1-3 mg/hour. Administration of calcium ions, or the use of a cardiac pacemaker, may also be considered. Haemodialysis removes less than 1% labetalol hydrochloride from the circulation.
Further treatment should be provided as clinically appropriate or as advised by a national anti-toxins laboratory, if available.
Ask anything about Labetalol Synchrony 5mg/ml solution for injection. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.
We use essential cookies to make the site work. We would also like to set optional cookies to understand how the site is used, so we can improve it. We will not set optional cookies unless you accept. See our cookie policy and privacy policy.